Public Employees Retirement System of Ohio grew its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 10.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,779 shares of the company's stock after buying an additional 8,533 shares during the period. Public Employees Retirement System of Ohio owned 0.19% of Prestige Consumer Healthcare worth $6,617,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. ORG Partners LLC purchased a new stake in Prestige Consumer Healthcare during the second quarter valued at about $39,000. Blue Trust Inc. raised its position in shares of Prestige Consumer Healthcare by 106.9% in the second quarter. Blue Trust Inc. now owns 867 shares of the company's stock valued at $63,000 after purchasing an additional 448 shares during the period. Raymond James & Associates boosted its holdings in Prestige Consumer Healthcare by 10.1% in the 2nd quarter. Raymond James & Associates now owns 117,802 shares of the company's stock worth $8,111,000 after buying an additional 10,823 shares during the period. Leeward Investments LLC MA grew its stake in Prestige Consumer Healthcare by 5.6% in the 2nd quarter. Leeward Investments LLC MA now owns 406,093 shares of the company's stock valued at $27,960,000 after buying an additional 21,549 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in Prestige Consumer Healthcare by 2.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 25,100 shares of the company's stock valued at $1,728,000 after acquiring an additional 500 shares during the period. Institutional investors own 99.95% of the company's stock.
In other news, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now directly owns 18,365 shares in the company, valued at approximately $1,505,930. This represents a 33.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 in the last quarter. Insiders own 1.60% of the company's stock.
A number of equities analysts have recently commented on PBH shares. Sidoti lowered Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a report on Monday, December 9th. DA Davidson restated a "buy" rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group reaffirmed a "hold" rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Finally, StockNews.com downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $85.25.
Check Out Our Latest Research Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare stock opened at $82.26 on Friday. The business has a 50-day simple moving average of $77.85 and a 200 day simple moving average of $72.35. Prestige Consumer Healthcare Inc. has a 52 week low of $57.95 and a 52 week high of $86.36. The stock has a market cap of $4.06 billion, a price-to-earnings ratio of 20.01, a PEG ratio of 2.35 and a beta of 0.49. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to analysts' expectations of $282.09 million. During the same period in the prior year, the business earned $1.07 earnings per share. Prestige Consumer Healthcare's revenue for the quarter was down .9% compared to the same quarter last year. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.